Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Depreciation and Depletion (2021 - 2025)

Historic Depreciation and Depletion for InMed Pharmaceuticals (INM) over the last 5 years, with Q2 2025 value amounting to $12206.0.

  • InMed Pharmaceuticals' Depreciation and Depletion rose 12437.5% to $12206.0 in Q2 2025 from the same period last year, while for Jun 2025 it was $50204.0, marking a year-over-year increase of 515.91%. This contributed to the annual value of $50204.0 for FY2025, which is 515.69% up from last year.
  • Latest data reveals that InMed Pharmaceuticals reported Depreciation and Depletion of $12206.0 as of Q2 2025, which was up 12437.5% from $12203.0 recorded in Q1 2025.
  • Over the past 5 years, InMed Pharmaceuticals' Depreciation and Depletion peaked at $14242.0 during Q4 2023, and registered a low of $4217.0 during Q3 2021.
  • For the 5-year period, InMed Pharmaceuticals' Depreciation and Depletion averaged around $10249.0, with its median value being $11394.5 (2023).
  • Its Depreciation and Depletion has fluctuated over the past 5 years, first plummeted by 5788.17% in 2024, then surged by 12437.5% in 2025.
  • InMed Pharmaceuticals' Depreciation and Depletion (Quarter) stood at $6246.0 in 2021, then rose by 28.98% to $8056.0 in 2022, then skyrocketed by 76.79% to $14242.0 in 2023, then decreased by 14.27% to $12209.0 in 2024, then decreased by 0.02% to $12206.0 in 2025.
  • Its Depreciation and Depletion stands at $12206.0 for Q2 2025, versus $12203.0 for Q1 2025 and $12209.0 for Q4 2024.